Alzheimer's Disease - Test Your Medical IQ

Title: Alzheimer's Disease - Test Your Medical IQCategory: MedicineNet QuizCreated: 2/2/2012 5:35:00 PMLast Editorial Review: 3/11/2015 5:29:02 PM
Source: MedicineNet Alzheimer - Category: Geriatrics Source Type: news

Related Links:

This study measured stimulus-evoked brain tissue oxygenation changes in a mouse model of Alzheimer disease (AD) and further explored the influence of exercise and angiotensin II-induced hypertension on these changes. In vivo two-photon phosphorescence lifetime microscopy was used to investigate local changes in brain tissue oxygenation following whisker stimulation. During rest periods, PO2 values close to the arteriolar wall were lower in the AD groups and the PO2 spatial decay as a function of distance to arteriole was increased by hypertension. During stimulation, tissue PO2 response had a similar spatial dependence acr...
Source: Neuroscience Letters - Category: Neuroscience Source Type: research
In conclusion, melatonin ameliorates memory deficits in STZ-induced hyperglycemia rats by restoring insulin signaling pathway which is independent of its effects on blood glucose and insulin levels. Thus, melatonin might be a therapeutic option for helping patients suffering from diabetes and contributed to Alzheimer's disease.
Source: Neurochemistry International - Category: Neuroscience Source Type: research
In this study, it was found that acetaldehyde treatment induced excessive mitochondrial fragmentation, impaired mitochondrial function and caused cytotoxicity in cortical neurons and SH-SY5Y cells. Further analyses showed that acetaldehyde induced the phosphorylation of mitochondrial fission related protein dynamin-related protein 1 (Drp1) at Ser616 and promoted its translocation to mitochondria. The elevation of Drp1 phosphorylation was partly dependent on the reactive oxygen species (ROS)-mediated activation of c-Jun-N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK), as N-acetyl-l-cysteine (NAC) pre...
Source: Redox Biology - Category: Biology Source Type: research
Authors: Tolar M, Abushakra S, Sabbagh M Abstract Development of disease-modifying treatments for Alzheimer's disease (AD) has been challenging, with no drugs approved to date. The failures of several amyloid-targeted programs have led many to dismiss the amyloid beta (Aβ) hypothesis of AD. An antiamyloid antibody aducanumab recently showed modest but significant efficacy in a phase 3 trial, providing important validation of amyloid as a therapeutic target. However, the inconsistent results observed with aducanumab may be explained by the limited brain penetration and lack of selectivity for the soluble A&beta...
Source: The Journal of Alzheimers Association - Category: Psychiatry Tags: Alzheimers Dement Source Type: research
Authors: Nikolac Perkovic M, Pivac N Abstract Alzheimer's disease is a complex and heterogeneous, severe neurodegenerative disorder and the predominant form of dementia, characterized by cognitive disturbances, behavioral and psychotic symptoms, progressive cognitive decline, disorientation, behavioral changes, and death. Genetic background of Alzheimer's disease differs between early-onset familial Alzheimer's disease, other cases of early-onset Alzheimer's disease, and late-onset Alzheimer's disease. Rare cases of early-onset familial Alzheimer's diseases are caused by high-penetrant mutations in genes coding for...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Epileptic activity without visible convulsions is common in Alzheimer's disease (AD) and may contribute adversely to the disease progress and symptoms. Transgenic mice with amyloid plaque pathology also display epileptic seizures, but those are too infrequent to assess the effect of anti-epileptic treatments. Besides spontaneous seizures, these mice also display frequent epileptic spiking in epidural EEG recordings, and these have provided a means to test potential drug treatment to AD-related epilepsy. However, the origin of EEG spikes in transgenic AD model mice has remained elusive, which makes it difficult to relate el...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Roche is testing its "brain shuttle" in humans, with the Swiss drugmaker hoping to rejuvenate the theory that removing amyloid plaques from the brains of patients with Alzheimer's disease will prove effective despite repeated failures.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
Researchers at Lawrence Berkeley National Laboratory have developed synthetic peptide-coated magnetic beads that can be used to detect the presence of misfolded proteins in blood samples. Misfolded proteins are a factor in a number of diseases, inclu...
Source: Medgadget - Category: Medical Devices Authors: Tags: Diagnostics Nanomedicine Neurology Public Health Source Type: blogs
(Technical University of Denmark) Scientists prove that ergothioneine, an important compound that may be used to delay the onset of diseases such as Alzheimer's and dementia, can be produced in baker's yeast.
Source: EurekAlert! - Biology - Category: Biology Source Type: news
(University of Minnesota) Research update from the University of Minnesota Center for Drug Design on an early detection device for Alzheimer's disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
More News: Alzheimer's | Geriatrics